Open for comments Open until Request commenting lead permission
We have updated this service so that members of the same organisation can now collaborate on a joint online response.
Read our blog to learn more.
Digital technologies aim to support self-management of asthma by providing a digital personalised asthma action plan (PAAP), tailored education and tools for tracking symptoms and medication. These features may improve medication adherence and asthma control, reduce exacerbations and improve quality of life.
Technologies included in the scope vary in terms of:
target population
mode of delivery (apps, online platforms and additional hardware requirements)
features and components.
The final scope specified that the technologies should function independently of clinical oversight from healthcare professionals such as through remote monitoring. It also specified that, as a minimum, the technologies should include:
access to a PAAP
evidence-based education on self-management
tracking and monitoring of symptoms or lung function.
The technologies identified also had the additional following features:
inhaler technique support
trigger alerts
environment alerts
reminders for medication or appointments
medication tracking (except Luscii).
Digital technologies are offered after diagnosis or treatment initiation or during routine reviews. They could be offered in:
primary care, such as GP surgeries
secondary care, such as hospitals or specialist clinics
tertiary centres
the community, such as pharmacies or schools.
They could also be used by carers, parents and community workers to support children or adults who cannot self-manage their condition.
Details of the 8 technologies included in this assessment are in table 1. Further detail on mode of delivery and features (including symptoms and peak flow monitoring and PAAPs are storage and management) is in table 2 of the external assessment group (EAG) report. Costs were estimated by the EAG using information provided by companies (see appendix C2 of the EAG's report). Seven technologies are currently in use within the NHS and 1 (AsthmaTuner) reported a planned release in 2026.
Technology (company) | CE or UKCA mark | Target users | Upfront cost including hardware, £ | Estimated technology cost per patient per year, £ |
|---|---|---|---|---|
Asthmahub (ICST) | I | People 18 years and over | 29 | 0 |
Asthmahub for parents (ICST) | I | Children and parents or carers | 29 | 0 |
AsthmaTuner (MediTuner) | IIb | People 6 years and over and healthcare professionals | Public price not disclosed (commercial in confidence) | Public price not disclosed* |
Digital Health Passport (Tiny Medical Apps) | I | People 5 years and over and parents or carers | 77 | 0 |
Luscii (Luscii Healthtech BV) | IIa | All age groups and healthcare professionals | 8.50 | 180 |
myAsthma | I | People 13 years and over | 35 | 30 |
RDMP | I | People 16 years and over and healthcare professionals | 112 | 180 |
Smart Asthma (Smart Respiratory Products Ltd) | IIa | People 5 years and over and parents or carers | 66.65 | 0 |
Abbreviations: CE, Conformité Européene; ICST, Institute of Clinical Science and Technology; RDMP, Respiratory Disease Management Platform; UKCA, UK Conformity Assessed.
For information, Carbon Reduction Plans for UK carbon emissions, or a commitment to reducing greenhouse gas emissions and achieving net zero, for 3 technologies are published here:
Smart Respiratory Products Ltd: Carbon Reduction Plan.
The following companies did not disclose a Carbon Reduction Plan for UK carbon emissions or a net zero commitment:
ICST
Luscii Healthtech BV
MediTuner
Tiny Medical Apps.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions